Published: June 06, 2026, 07:01 UTC
Restless legs syndrome (RLS) affects an estimated 5 to 10 percent of adults, causing uncomfortable sensations in the legs and an irresistible urge to move them, particularly at night. Sleep fragmentation is the rule rather than the exception. The standard pharmacological approach relies on dopamine receptor agonists such as pramipexole and ropinirole, which target D2-like receptors including the D3 subtype. But these drugs carry significant drawbacks: augmentation (a paradoxical worsening of symptoms over time) and impulse control disorders in a subset of patients.
A new review article published as an Advance Article in the journal SLEEP reexamines the pharmacology of the dopamine D3 receptor specifically in the context of RLS, arguing that a more refined understanding of D3 signaling may open the door to better-targeted therapies.
The author, Maria P. Mogavero, synthesizes evidence from preclinical models, neuroimaging studies, and clinical observations to argue that the D3 receptor has been underexplored as a specific therapeutic target. Current dopamine agonists bind broadly across D2-like receptors, and their efficacy in RLS is thought to be mediated primarily through D3 receptor activation. Yet the side effects may stem from action at other receptor subtypes or from the specific signaling pathways engaged.
The review places particular emphasis on the distinction between G protein signaling and beta-arrestin signaling downstream of D3 receptor activation. Recent research in animal models has shown that subtle differences in how a compound engages these pathways can determine whether it reduces periodic limb movements or makes them worse. A study published in SLEEP in May 2026 found that the selective D3 ligand PG01042, a partial agonist at both G proteins and beta-arrestin, reduced leg movements in an iron-deficient rat model of RLS and improved sleep. A structurally similar compound, PG01037, which differed only in its effect on G protein signaling, worsened symptoms.
Mogavero’s article arrives at a moment when the field is actively reconsidering whether broad D2-like agonism is the right approach. The concept of biased agonism, where a drug selectively activates some downstream pathways over others, is gaining traction in neurology. For RLS, a therapy that engages D3 receptors with the right signaling balance could in theory provide symptom relief without the long-term risks of augmentation or impulse control disorders.
The review is limited by the available data. Most existing clinical trials have tested drugs developed before the era of biased agonism, and the new selective D3 compounds remain in preclinical stages. Human studies are needed to determine whether the signaling profiles that look promising in rodents translate to patients.
For sleep clinicians, the message is that the pharmacology of RLS may be on the verge of a shift. The current tools work for many patients, but the next generation of therapies may look fundamentally different.
Source: Mogavero MP. Rethinking Dopamine D3 Receptor Pharmacology in Restless Legs Syndrome. Sleep, 2026. DOI: 10.1093/sleep/zsag156